Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II trial of weekly docetaxel, estramustine and prednisone versus docetaxel and prednisone in patient with hormone-resistant prostate cancer

Trial Profile

Randomized phase II trial of weekly docetaxel, estramustine and prednisone versus docetaxel and prednisone in patient with hormone-resistant prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2008

At a glance

  • Drugs Docetaxel; Estramustine; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Sep 2008 Results published in JCO.
    • 18 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top